We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Antisoma | LSE:ASM | London | Ordinary Share | GB0055696032 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.325 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
21/2/2008 13:45 | Does anyone else think that the share price reaction today seems over-cooked? Don't get me wrong - I'm not complaining, and perhaps its simply recovering some of the inexplicable drop in share price over the last 9 months, but... Anyone any thoughts? | jsteveuk | |
21/2/2008 13:27 | monthly chart nice and vertical :) | dasv | |
21/2/2008 13:01 | I reckon so...early days here | davenic | |
21/2/2008 12:58 | Back to 50p + then. | driver101 | |
21/2/2008 10:47 | A stunning performance, sure to be picked up in tomorrow morning's press.... | davidbennett | |
21/2/2008 10:12 | Excellent stuff. Encouraging to see 1409 go into the clinic, cash position is very healthy, looking to pick up assets cheaply (given the current climate) - either via licensing or company acquisition! All good stuff, and with a nice steady newsflow in 2008: ASA404 - Start of enrollment in NSCLC phIII - H1-08 AS1411 - Data from first cohort of AML phII - H1-08 ASA404 - Median survival data from Prostate phII - H2-08 AS1402 - Start of enrollment into breast cancer phII - H2-08 Only surprise is the comment that they are not looking to out-license any of the current assets. Perhaps just positioning, but I would have thought that they would always be willing to talk if the right offer came along ;0) | jsteveuk | |
21/2/2008 09:43 | yes indeed. Perfect time to have cash in the bank. If ASM could diversify a little perhaps those put off by risk would come flocking. | dasv | |
21/2/2008 09:32 | I like this... INTERVIEW Antisoma to take rest of pipeline forward alone, possible acquisition LONDON (Thomson Financial) - Antisoma's chief executive Glyn Edwards and CFO Raymond Spencer told Thomson Financial News this morning that now would be a good time for the company to make an acquisition as it has a strong cash position and many sector peers are in financial difficulty. "We remain interested in doing a more substantial acquisition and there's never been a better time when companies are in financial difficulty to pick up really great projects through the acquisition of companies," Edwards said during an interview following the company's half year results announcement where it revealed a cash position in excess of 50 mln stg with substantial further payments due from a licensing deal with Novartis. He also said that the company, which specialises in buying in cancer treatments and putting them into clinical development, was not looking to make any more partnership deals but instead plans to take the products forward itself. "Our current intention is not to partner the other products, we want to take them forward ourselves," he said, adding that the company expected 355 mln usd in milestone payments from Novartis on top of the 25 mln that will be paid when the drug, ASA404, enters late-stage trials. The company expects to have enough cash to last it "well into the future" according to Edwards. Finance chief Spencer explained: "We had 50 mln stg at Dec 31 and ... we also get a 25 mln usd milestone when 404 goes into the phase 3 study in non-small cell lung cancer which Novartis say should happen soon, so that will boost our cash, and for the 6 months ended 31 Dec when you strip out movements in creditors, debitors etc we had a cash burn of around about 10.5 mln stg." Edwards also said that the company will inlicense one or two products within the next 12 months, and potentially before. "We haven't done any inlicensing for about 18 months or so and our traditional rate of inlicensing is one per year, and the reason we didn't do that is that we've been focused on getting this partnership deal with Novartis and getting that up and running. "But now we've been working for some time on finding new things and so you can expect that there will be some inlicensing announcements made in the next 12 months, either one or 2 products in that period," he said. "Our bottom line is that we look around us and we're in a very strong position with both the Novartis deal and our strong cash," he added. | davidbennett | |
21/2/2008 09:14 | not bad going "In the first half, the UK-based company booked a pretax profit of 4.1 mln stg against a loss of 7.5 mln stg last time, on revenues of 16.5 mln stg vs 0.3 mln last time. " | dasv | |
21/2/2008 09:11 | RNS all sounds good | davenic | |
21/2/2008 08:49 | Actually, the market in this could become quite thin. If that becomes the case it could really move. Look at OXB which went from 18.75 to 30 in a metter of days, one moment there were sellers galore at 18.75, next they all disappear and the price soars. Same could happen here, all IMO of course. | davidbennett | |
21/2/2008 08:45 | Looks that way... I can see this heading further up as the day progresses and investors see what value is here. I know that there is a lunch briefing and presentation at the offices of Buchanan Communications this afternoon at 12.45pm... can't see anything negative only positives coning out of this meeting and further buying.... | davidbennett | |
21/2/2008 08:33 | Champagne anyone? | zagrem | |
20/2/2008 22:42 | dasv, been little or no posts since then! > looking good today Cos we switched thread. Just read comment about it being results day tomorrow, therefore now expecting a red day, everything seems to fall after results these days. | 1leigh | |
20/2/2008 20:19 | Results tomorrow, should be interesting. Update on progress, burn rate etc. Perhaps they should highlight the excellent position this company is now in. | thefod | |
20/2/2008 18:42 | gnomet ive been ere 5 years youre welcome mate, may you bring us some due luck. | bluechef | |
20/2/2008 17:39 | gnonmet2 I've been on this thread since April 2007. There's been little or no ramping since then. | dasv | |
20/2/2008 17:16 | Take note folks, some of us at least have moved thread now. | gnomet2 | |
20/2/2008 17:12 | Ok, I'll move over to this one too. I bought in with a small stake last Friday. I appeal to everyone to make it an informative thread, not a ramper's vehicle full of misleading nonsense. | gnomet2 | |
20/2/2008 15:43 | Lets hope its our turn soon. OXB moved higher on similar rumours, come on spark one off about ASM. | bluechef | |
20/2/2008 15:38 | Not surprising, CEN on drift, wonder if there's a switch going on. That one's stalled and makes me wonder if people doubting CEN's deal. Maybe they are turning to a safer sector play. If so, let them join up. | zagrem | |
20/2/2008 15:29 | looking good today | davenic | |
19/2/2008 20:06 | me neither. Like putting on an old pair of slippers.... | 1leigh | |
18/2/2008 21:58 | Certainly not me. | scruff1 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions